Clinical Evaluation of Herbal Medicine for Oligospermia

Hafeez, Muhammad; Ahmed, Afzal; Usmanghani, Khan; Mohiuddin, Ejaz; Asif, Hafiz Muhammad; Akram, Muhammad; Rehman, Riaz Ur

doi:10.3923/pjn.2011.238.240

Cited by 10 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infertility refers to inability to achieve pregnancy after twelve months of regular and unprotected intercourse (1, 2). About 40-50% of infertilities are due to male sexual dysfunction, as one out of twenty men suffer from this issue, worldwide (3-6).…”

Section: Introductionmentioning

confidence: 99%

“…The majority of infertile and sub fertile men have deficiency in the semen quality which is determined by low sperm numbers, sperm morphology and insufficient sperm motility. Other cases may appear by hormonal imbalances, anatomical problems and genetic defects (1, 2). Male fertility is the direct consequence of spermatogenesis, a multistep process in seminiferous tubules of testis, which is highly regulated by sophisticated hormonal signaling pathways (6, 7).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of fertility parameters with Tribulus Terrestris and Anacyclus Pyrethrum treatment in male rats

et al. 2019

View full text Add to dashboard Cite

Objective Anacyclus Pyrethrum (AP) and Tribulus Terrestris (TT) have been reported as male infertility treatment in several studies; however, in Iranian traditional medicine these two plants are prescribed simultaneously. In this study, we aimed to determine the effects of AP and TT extracts both separately and simultaneously on the male Wistar rat fertility parameters.Materials and Methods 32 male Wistar rats were divided into 4 groups: Control, TT, AP, and AT treated groups. Treatment continued for 25 days and rats were weighed daily. Their testes were dissected for histological studies. Sperm analysis including sperm count, viability and motility were performed. Serum was obtained to evaluate testosterone, LH and FSH levels. Histological studies were conducted to study Leydig, and Sertoli cells, spermatogonia and spermatid cell numbers, and to measure seminiferous diameter and epithelium thickness.Results Sperm count increased in all the treatment groups. Sperm viability and motility in AT and AP groups were elevated. TT and AT groups showed significantly increased testosterone level compared to control group (P=004, P=0.000, respectively) and TT, AP and AT treatment groups showed increased LH level (P=0.002, P=0.03 and P=0.000, respectively) compared to control, while only AT group showed increased FSH (p=0.006) compared to control. Histological studies showed significant increase of spermatogonia, Leydig and Sertoli cell numbers and epithelial thickness in AT group compared to other groups. All the treatment groups had higher number of Leydig, spermatogonia and spermatid cells.Conclusion TT and AP improved sexual parameters; however, their simultaneous administration had higher improving effects on studied parameters.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Improvement of fertility parameters with Tribulus Terrestris and Anacyclus Pyrethrum treatment in male rats

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Two independent reviewers evaluated the remaining 197 potentially relevant trials of which 175 were deemed to be relevant. From these, the largest 100 RCTs reporting data from 24 542 men (range: 80–2772 men) were used to identify and report outcomes ( Abdel-Maguid and Othman, 2010 ; Fang et al , 2010 ; Fayez et al , 2010 ; Kovacic et al , 2010 ; Abdel-Meguid et al , 2011 ; Azadi et al , 2011 ; Balaban et al , 2011 ; Figueira Rde et al , 2011 ; Hafeez et al , 2011 ; Safarinejad, 2011 ; Safarinejad et al , 2011 ; Selice et al , 2011 ; Turhan et al , 2011 ; Wilding et al , 2011 ; Amirzargar et al , 2012 ; Colacurci et al , 2012 ; El-Khayat et al , 2012 ; Lee et al , 2012 ; Mansour Ghanaie et al , 2012 ; Parmegiani et al , 2012 ; Rago et al , 2012 ; Safarinejad et al , 2012 ; Velaers et al , 2012 ; Azizollahi et al , 2013 ; De Vos et al , 2013 ; Gopinath et al , 2013 ; Kang et al , 2013 ; Leandri et al , 2013 ; Majumdar and Majumdar, 2013 ; Pan et al , 2013 ; Worrilow et al , 2013 ; Akin et al , 2014 ; Karamahmutoglu et al , 2014 ; Kolahdooz et al , 2014 ; Moslemi Mehni et al , 2014 ; Nematollahi-Mahani et al , 2014 ; Pourmand et al , 2014 ; Raigani et al , 2014 ; Romany et al , 2014 ; Wang et al , 2014 ; Calogero et al , 2015 ;…”

Section: Resultsmentioning

confidence: 99%

Outcome reporting across randomized controlled trials evaluating potential treatments for male infertility: a systematic review

Rimmer

Howie

Subramanian

et al. 2022

Human Reproduction Open

View full text Add to dashboard Cite

STUDY QUESTION What are the primary outcomes and outcome measures used in randomized controlled trials (RCTs) evaluating potential treatments for male infertility in the last 10 years? SUMMARY ANSWER Outcome reporting across male infertility trials is heterogeneous with numerous definitions and measures used to define similar outcomes. WHAT IS KNOWN ALREADY No core outcome set for male infertility trials has been developed. Male infertility trials are unique in that they have potentially three participants, a man, a female partner and their offspring and this will likely lead to significant variation in outcome reporting in randomized trials. STUDY DESIGN, SIZE, DURATION A systematic review of RCTs mapping outcomes and outcome measures evaluating potential treatments for men with infertility registered in the Cochrane Register of Controlled Trials (CENTRAL) between January 2010 and July 2021. PARTICIPANTS/MATERIALS, SETTING, METHODS Abstract screening and study selection was undertaken in duplicate using a review protocol that was developed prior to commencing the review. No risk of bias assessment was undertaken as this review aims to report on outcome reporting only. MAIN RESULTS AND THE ROLE OF CHANCE One hundred and seventy-five RCTs were identified, and given the large number of studies we limited our review to the 100 largest trials. Seventy-nine different treatments were reported across the 100 largest RCTs including vitamin and dietary supplements (18 trials), surgical treatments (18 trials) and sperm selection techniques (22 trials). When considering the largest 100 trials (range: 80–2772 participants), 36 primary and 89 secondary outcomes were reported. Forty-seven trials reported a primary outcome and 36 trials clearly defined their primary outcome. Pregnancy outcomes were inconsistently reported and included pregnancy rate (51 trials), pregnancy loss including miscarriage, ectopic pregnancy, stillbirth (9 trials) and live birth (13 trials). Trials consistently reporting the same outcome frequently used different definitions. For example, semen quality was reported by 75 trials and was defined in 7 different ways, including; the World Health Organization (WHO) 2010 criteria (32 trials), WHO 1999 criteria (18 trials), WHO 1992 criteria (3 trials), WHO 1999 and 1992 criteria (1 trial) and the Kruger strict morphology criteria (1 trial). LIMITATIONS, REASONS FOR CAUTION We only evaluated the 100 largest trials published in the last 10 years and did not report outcomes on the remaining 75. An outcome was included as a primary outcome only if clearly stated in the manuscript and we did not contact authors to clarify this. As our review mapped outcomes and outcome measures, we did not undertake an integrity assessment of the trials included in our review. WIDER IMPLICATIONS OF THE FINDINGS Most randomized trials evaluating treatments for male infertility report different outcomes. Only half of the RCTs reported pregnancy rate and even fewer reported live birth; furthermore, the definitions of these outcomes varies across trials. Developing, disseminating and implementing a minimum data set, known as a core outcome set, for male infertility research could help to improve outcome selection, collection and reporting. STUDY FUNDING/COMPETING INTEREST(S) A.P.—chairman of external scientific advisory committee of Cryos International Denmark ApS, member of the scientific advisory board for Cytoswim LDT and ExSeed Health. Guest lecture at the ‘Insights for Fertility Conference’, funded by MERK SERONO Limited. M.v.W.—holds a ZON-MW research grant. No external funding was obtained for this study.

show abstract

“…Thus, reproductive health has recently helped change the areas researchers are interested in. Infertility is the inability to give birth to a baby after one year or more of regulars exist mating and it is considered a fundamental defect of the venereal system ( Hafeez et al, 2011 ). It is very hard to define the causes of male infertility due to cultural restrictions.…”

Section: Introductionmentioning

confidence: 99%

Effect of Filgrastim on adult male rats’ fertility and reproductive performance

Saber

Alduweesh

El‐Rahman

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

Filgrastim is a recombinant protein used in treatment neutropenia caused by myelosuppressive medications for patients with non-myeloid cancer. However, its effect in male fertility is not clear. So, the current work aims to clarify the effect of Filgrastim on the reproductive state in Wistar rats. Eighteen (18) male Wistar rats were divided into three groups (6/each). Group (I) where the rats were injected with 0.5 ml/kg/day of distilled water and served as Control Group. The Group (II) animals received intraperitoneal injection of therapeutic dose of 30.83 mcg/kg/day of Filgrastim for one week. The Group (III) rats received the same dose by the same route of Filgrastim for two weeks. Sera of blood samples were processed for serum follicle stimulating hormone (FSH), luteinizing hormone (LH), testosterone (TS). Semen analysis and resazurine reduction test (RRT) were performed. Assaying for malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) was done. The testes were retrieved for histopathological and immunohistochemical studies for caspase-3 detection. Our results revealed that filgrastim affects sperm morphology, significantly decreased the RRT and the reproductive hormones level, elevated the oxidative stress status and induced several histopathological changes in testes with an increased in immunoexpression of caspase-3 in testes tissues. The results of this work demonstrated that Filgrastim may had a deleterious effect on male fertility.

show abstract

Clinical Evaluation of Herbal Medicine for Oligospermia

Cited by 10 publications

References 10 publications

Improvement of fertility parameters with Tribulus Terrestris and Anacyclus Pyrethrum treatment in male rats

Improvement of fertility parameters with Tribulus Terrestris and Anacyclus Pyrethrum treatment in male rats

Outcome reporting across randomized controlled trials evaluating potential treatments for male infertility: a systematic review

Effect of Filgrastim on adult male rats’ fertility and reproductive performance

Contact Info

Product

Resources

About